Hypo-glycosylated human follicle-stimulating hormone (hFSH 21/18 ) is much more active in vitro than fully-glycosylated hFSH ( 
I-hFSH
21/18 tracer than hFSH 24 tracer was observed in all competitive binding assays. In addition, higher binding of hFSH 21/ 18 was noted in association and saturation binding assays, in which twice as much hFSH 21/18 was bound as hFSH 24 . This suggests that more ligand binding sites are available to hFSH 21/18 in FSHR than to hFSH 24 . Hypo-glycosylated hFSH 21/18 also bound rat FSHRs more rapidly, exhibiting almost no lag in binding, whereas hFSH 24 specific binding proceeded very slowly for almost the first hour of incubation.
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Introduction
Carbohydrate heterogeneity results in FSH preparations composed of populations of acidic isoforms (Ulloa-Aguirre and Chappel, 1982; Ulloa-Aguirre et al., 1992a , 1992b Wide, 1985 Wide, , 1987 . The ratios of these isoforms have been shown to vary under physiological conditions, with the less acidic more abundant in young women and at mid-menstrual cycle, while more acidic isoforms are more abundant in older women and in men (Wide, 1982 (Wide, , 1985 Wide and Bakos, 1993; Zambrano et al., 1995) .
Partial N-glycosylation of hFSHb produces two hFSH glycoforms, the classical fully-glycosylated hFSH, which possesses all four N-glycans, and a hypo-glycosylated hFSH, which lacks either one or both b subunit N-glycans (Walton et al., 2001 ). These glycoforms are most readily evaluated by FSHb Western blotting, which reveals two bands, a 24,000 M r band, that represents the fully-glycosylated form of the subunit (FSHb 24 ) , and a 21,000 M r band, that represents a hypo-glycosylated subunit (FSHb 21 ). In principle, hFSH 21 should represent a less acidic hFSH isoform. Indeed, we have reported that above pI 5.4 only hFSH 21 was found in chromatofocusing fractions (Walton et al., 2001 ). However, hFSH 21 was also found in the less than pI 4.0 fractions and in all others in between, along with hFSH 24 (Bousfield et al., 2008; Walton et al., 2001) . As the activities of hFSH isoforms possessing more 21,000 M r than 24,000 M r FSHb were greater than those possessing more 24,000 M r FSHb, we proposed the hypothesis that hypo-glycosylation of hFSHb increased FSH biological activity (Walton et al., 2001) . Analysis of hFSH derived from individual human pituitaries revealed an age-related decreased abundance of hFSHb 21 indicating the loss of a potentially more active FSH variant. Western blots of virtually all pituitary and urinary hFSH preparations exhibit both hFSHb subunit variants, regardless of purity (Bousfield et al., 2007; Walton et al., 2001) . Exceptions included less acidic FSH isoform fractions that possessed only the 21,000 M r hFSHb variant mentioned above.
In chromatofocusing experiments, the least acidic hFSH isoform fractions consisted of hFSH 21 , but were heavily contaminated with hLH (Walton et al., 2001) . We speculated that the 1-2% FSH activity associated with purified pituitary hLH preparations might consist of the hypo-glycosylated hFSH 21 glycoform, and captured it with an FSH-specific antibody column. Since reverse-phase HPLC is known to produce the 24,000 M r hFSHb variant in high purity (Walton et al., 2001) , we isolated hFSHb 24 and combined it with hCGa to produce a semi-synthetic, fully-glycosylated hFSH preparation that would enable us to compare the biological activities of both glycoforms.
Materials and methods

Hormone preparations
Three purified hLH preparations were obtained from Anne Hartree following her retirement from Cambridge University (Walton et al., 2001 ). An additional hLH preparation was obtained from Dr. A.F. Parlow and the National Hormone and Pituitary Program (Ward et al., 1986) , along with the hFSH reference preparation, AFP7298A (8560 IU/mg). Recombinant hFSH was purified from a stable, transformed GH 3 cell line, which was the generous gift of Dr. Irving Boime, Washington University, St. Louis, MO. Details of its isolation and characterization will be described in a separate publication. Mutant recombinant hFSH bT26A, expressed in insect cells, was provided by Dr. James A. Dias, Wadsworth Center, Albany, NY (Fox et al., 2001) . Purification of hFSH glycoforms is described in the supplement. Equine FSH was isolated from horse pituitaries in our laboratory, following our usual procedures (Bousfield and Ward, 1984) . The hCGa preparation was purified as previously reported (Bousfield et al., 1985) . HiTrap-NHS columns and Superdex 75 gel filtration columns were obtained from GE Healthcare, Piscataway, NJ.
Antibodies
A monoclonal antibody 46.3H6.B7, which recognized hFSH and hFSHb, was also provided by Dr. Dias (Bousfield et al., 2007) . This antibody was coupled to 1-ml HiTrap-NHS columns following the manufacturer's instructions. The anti-hFSHb monoclonal antibody RFSH20 (recognizes both FSHb and FSH), and anti-a subunit antibody HT13 (recognizes all human a-subunits and glycoprotein hormones), were provided by Dr. Jean-Michel Bidart, Institut de Cancérologie Gustave-Roussy, Paris, France (Walton et al., 2001 ).
Glycoform nomenclature
The hFSH glycoforms are differentiated by the relative molecular weights of the FSHb subunit Western blot bands, as indicated by a trailing superscript. Thus, pituitary and urinary hFSH preparations possessing both 21,000 and 24,000 M r hFSHb variants are designated as hFSH 24/21 , where the first number indicates the more abundant form. FSH glycoform preparations are designated as either fully-glycosylated hFSH 24 (formerly tetra-glycosylated hFSH) and hypo-glycosylated hFSH 21 (formerly di-glycosylated hFSH), or hFSH 21/18 . The latter is the variant characterized in the present study.
FSH glycoform characterization
Western blotting was carried out as described previously (Bousfield et al., 2007) . Primary antibodies typically employed were anti-hFSHb monoclonal antibody, RFSH20, anti-a subunit monoclonal antibody, HT13. Oligosaccharides released from hFSH samples by PNGaseF digestion were analyzed by nano-electrospray mass spectrometry (Harvey et al., 2008) . FSH iodination and radioligand assay, association and saturation binding assays were performed as described previously (Bousfield and Ward, 1984; Liu et al., 1974 Liu et al., , 1984 . FSH and FSH subunit carbohydrate analyses were carried out as reported earlier (Bousfield et al., 2000) except that a Dionex ICS-5000 carbohydrate analyzer was employed. Detailed methods can be found in the supplement.
Edman degradation
Protein sequencing was carried out with an Applied Biosystems (Foster City, CA), Procise, model 494, automated sequencer, following the manufacturer's directions. Automated Edman degradation was carried out on 2 lg samples applied to Biobrene-coated glass fiber disks that were precycled in the sequencer prior to sample application. A typical experiment consisted of 10 Edman degradation cycles. Anti-hFSHβ RFSH20 Anti-α HT13 
Results
FSH glycoform isolation from hLH preparations
FSH was extracted from 100 mg batches of purified hLH three times using 46.3H6.B7 antibody columns. The average total hypo-glycosylated hFSH 21/18 recovery, based on extracting ten hLH batches three times each, was 44.2 ± 4.9 lg (mean ± standard deviation) per batch. FSH immunoactivity emerged from a 10 Â 300 mm Superdex 75 column in three peaks ( Fig. 1C-E) . The first of these, with retention times of 24.3-24.5 min., consisted of aggregated FSH. Hormone aggregation was confirmed by Western blotting following electrophoresis of reduced samples probed with anti-a monoclonal antibody, HT13 (Fig. 1A , lane 6), and non-reduced hFSH isoform samples probed with anti-hFSHb monoclonal antibody RFSH20 (Fig. 1B, (Fig. 1A) .
Preparation of fully-glycosylated hFSH 24
Reassociation of 874 lg HPLC-purified, 24,000 M r hFSHb (Walton et al., 2001 ) with 2640 lg hCGa, followed by gel filtration over Superdex 75, produced 834 lg fully-glycosylated hFSH in the heterodimer fraction (Fig. 2B, bar) . The heterodimer fraction possessed both hFSHb and hCGa subunit immunoactivities according to Western blots with RFSH20 and HT13 monoclonal antibodies, respectively (Fig 2B, insets 3 and 4, lane 1). A < 21,000 M r band was detected in the hFSHb Western blot that represented < 2% of the immunoactivity (the 24,000 M r band signal was saturated), much less than the 20% typically encountered in pituitary hFSH preparations (Fig. 2B , inset 3, lane 2).
FSH glycoform receptor-binding competition assays
The availability of hFSH glycoform preparations permitted us to test the hypothesis, based on previous studies, that the presence of the carbohydrate-deficient hFSHb 21 provides hFSH with greater FSH receptor-binding activity than hFSH variants possessing largely or exclusively the fully-glycosylated 24,000 M r FSHb 24 subunit (Walton et al., 2001) . Both hFSH glycoform preparations were compared with two other FSH preparations: a highly active, hypo-glycosylated eFSH preparation, purified in this laboratory (Bousfield and Ward, 1984) , that largely lacks bAsn 7 glycans (Dalpathado et al., 2006) , and a highly purified 70/30 mixture of hFSH 24 and hFSH 21 glycoforms, obtained from the National Hormone and Pituitary Program (AFP7298A). For reasons of clarity, we will limit labeling of b subunit relative molecular weight to hFSH preparations. All seven eFSH preparations purified in our laboratory were 90% hypo-glycosylated, possessing the 18,000 M r eFSHb band, while fully-glycosylated eFSHb had a relative molecular weight of 21,000, reflecting a combination of largely biantennary instead of tri-and tetra-antennary glycans attached to eFSH, with a significant percentage of these terminated with sulfate rather than sialic acid (Bousfield et al., 2004; Dalpathado et al., 2006 with fully-glycosylated hFSH 24 ( Fig. 3B and Table 1 ). (Fig. 4) .
FSHR association studies
The radioligand assay procedure routinely employed in this laboratory was modified for association studies because samples in the latter studies were removed at 15-min intervals, while separation of bound from free hormone in the former procedure involved a 20-min centrifugation step. In the modified assay, tubes were incubated at 37°C for the indicated times, then placed in an ice bath until incubation of all the tubes was completed, when all assay tubes were centrifuged together. To prevent continued FSH binding during the ice bath step, 2000-fold excess eFSH was added to each tube and the binding compared with tubes lacking cold hormone. A small, but statistically non-significant difference was noted between the binding curves, indicating that binding did not continue at 4°C, nor was there significant dissociation from the receptor. In subsequent experiments, tubes removed at different times were stored at 4°C in the absence of cold hormone and all were centrifuged together following removal of the last tubes from the incubator. Moreover, when receptor binding was measured following 3 h incubation at 4°C, no significant binding of I-eFSH binding to FSH receptors was observed in this experiment (data not shown), this tracer was not used in any studies reported herein.
In the association study (Fig. 5) Tables 3 and 4 ), which are rare in pituitary hFSH (Bousfield et al., 2008; Dalpathado et al., 2006; Green and Baenziger, 1988; Renwick et al., 1987) , but common in recombinant, insect cell-expressed glycoprotein preparations (Altmann et al., 1999) . We compared the pituitary hFSH glycoform subunit electrophoretic mobilities with those of wild type and glycosylation site-mutated, insect cell-expressed recombinant hFSH preparations in subunit-specific Western blots (Fig. 6 ). The hypo-glycosylated hFSHb immunoactivity migrated as 3 bands at M r 21,000, 20,000, and 18,0000 (Fig. 6A, (Weisshaar et al., 1991) , as compared with mostly triand tetra-antennary hFSH glycans presumably associated with the pituitary hFSHa preparation (Green and Baenziger, 1988; Renwick et al., 1987) . Only the wt recombinant insect hFSH and bT26A mutant recombinant insect hFSH preparations possessed both a and FSHb subunit bands indicating the presence of heterodimeric FSH. This was consistent with the observation of heterodimer peaks in the Superdex 75 gel filtration chromatograms for both the wt and bT26A preparations, while the a-subunit mutant chromatograms contained only the subunit peak (data not shown).
It is possible the aT80A mutant a subunit was below the limits of detection because, the absence of Asn 78 glycan affected HT13 antibody binding (Supplement Figs. 7 and 8 ). In both wt and bT26A recombinant insect hFSH preparations, the a subunit band mobilities were greater than those for any pituitary hFSH preparation a subunit bands, including hypo-glycosylated hFSH 21/18 . If 21,000 M r hFSHb indicated the di-glycosylated hFSH preparation reported earlier (Bousfield et al., 2007) , most of the glycans released by PNGaseF digestion should have come from the a subunit, yet its mobility was slower than a subunit associated with both heterodimeric insect hFSH preparations.
Hypo-glycosylated hFSHb subunit characterization
Hypo-glycosylated hFSH a and b subunits were separated from pooled hypo-glycosylated hFSH subunit fractions by 46.3H6.B7 immunopurification followed by Superdex 75 gel filtration of the unbound and bound fractions, respectively (Supplement Fig. 5 ). The yield of hypo-glycosylated hFSHb appeared to be greater than that of hFSHa, consistent with the absence of detectable a subunit immunoactivity in some subunit fraction Western blots ( Fig. 2A,  inset) . Automated Edman degradation revealed both hFSHb subunit N-terminal and internal amino acid sequences for the hypoglycosylated hFSHb preparation (Supplement Table 5 ), which was consistent with the appearance of fragment bands in Western blots of the subunit fraction ( Figs. 1 and 2 ). Only the a subunit N-terminal sequence was observed during Edman degradation of the hFSHa preparation (Supplement Table 6 ).
Neutral and amino sugar analysis of both a and b subunits revealed the presence of carbohydrate in both subunit preparations (Table 2) . Mannose yields were highest for all the monosaccharide residues detected in both subunit hydrolysates, consistent with quantitative MS data that indicated 60% of N-glycans released from hypo-glycosylated hFSH 21/18 were oligomannose, which possessed 3-9 mannose residues in addition to two GlcNAc residues (Supplement Table 3 ). Relative mannose abundance data indicated hypoglycosylated hFSH 21/18 glycans possessed an average of 4.7 mol mannose/mol glycan. Using this value, we normalized the compositions for both the a and b subunits. The results indicated a lower GlcNAc content in a subunit glycans, suggesting enrichment of oligomannose glycans in this subunit. Indeed, we previously reported oligomannose glycans largely associated with aAsn 56 (homologous to human aAsn 52 ) in horse LH preparations (Bousfield et al., 2004) .
Hypo-glycosylated FSHb subunit glycans possessed the typically higher fucose content as well as a higher GlcNAc content. The latter suggested more complex-type glycans were attached to this subunit than to the FSHa subunit. While the same relative amounts of galactose in both subunits suggested the same extent of branching in complex glycans, if FSHa in the subunit fraction represented free-a, rather than dissociated FSHa residue), which is exposed in the free subunit, but not in the intact hormone (Parsons et al., 1983) . Alternatively, the presence of complex glycans at one of the hFSH
21/18
a subunit glycosylation sites might be responsible for the slower migration during electrophoresis than insect-expressed FSHa subunits, which possessed exclusively oligomannose glycans. Compositions for the latter included GlcNAc, Man, and Fuc, but no Gal (Table 3) .
Discussion
Hypo-and fully-glycosylated hFSH preparation
The existence of two major hFSH glycoforms resulting from hFSHb macroheterogeneity was inferred from subunit-specific Western blots, which revealed hFSHb 24 and FSHb 21 bands accompanied by a single hFSHa band (Bousfield et al., 2007; Walton et al., 2001 ). Confirmation of hypo-glycosylated hFSH glycoform existence required isolation of this variant. While evaluating potential sources of di-glycosylated hFSH (now designated hFSH 21 ), the least acidic chromatofocusing fractions were considered because they possessed only the hFSHb 21 band in FSHb-specific Western blots (Walton et al., 2001 ). However, these fractions possessed only a small percentage of the total hFSH recovered. Moreover, significant hLH contamination was present in these fractions, which suggested examining preparations of this hormone (Timossi et al., 2000; Walton et al., 2001) . As 2.4 grams of hLH were available in the laboratory, we proceeded under the working hypothesis that the 1-2% FSH activity associated with most pituitary LH preparations represented hFSH 21 and anticipated recovering as much as 24 mg of this variant. However, the receptor-binding activity measurements grossly overestimated the FSH mass because purified hFSH 21/18 exhibited as much as 26-fold greater activity in rat FSH receptor-binding assays than the hFSH reference preparation used to quantify FSH (Fig. 3) . Thus, the actual mass of hFSH present in hLH was less than 1 mg and only 500 lg of that was recovered, which limited biochemical and biological characterization. As all other hFSH isoform fractions possessed a mixture of both hFSH 24 and hFSH 21 and no purification method was available at that time, fully-glycosylated hFSH 24 was reconstituted from HPLC-purified FSHb 24 combined with purified hCGa The latter was employed to avoid FSHb 21 contamination associated with HPLC-purified FSHa preparations (Walton et al., 2001 ).
FSH receptor binding
Before discussing the increased FSHR binding activities associated with hFSH 21/18 , it is important to realize that hypo-glycosylated hFSH preparations have been shown to be active in animal studies conducted by our collaborator, Dr. T.R. Kumar, University of Kansas Medical Center, Kansas City, KS. In vivo studies comparing hFSH 24 with hypo-glycosylated hFSH 21/18 preparations show a similar pattern of rapid onset of stimulation and higher level of ovarian response in Fshb null mice to hFSH 21/18 . These unpublished studies firmly establish the physiological significance of the receptor-binding data reported herein (Kumar, T.R., et al., manuscript in preparation). preparations. The unexpectedly high receptor-binding activity of hFSH 21/18 represented almost 10-fold greater activity than had been reported for other carbohydrate-deficient hFSH preparations. Chemically deglycosylated hFSH was reported to be as active as, or up to 3-fold more active than native hFSH in porcine and bovine FSH receptor assays (Calvo et al., 1986) . Recombinant hFSH preparations produced mixed results when FSHb glycosylation sites were mutated to prevent glycan addition. In one study, the activity of the recombinant, HEK293 cell-derived mutant hFSH preparation, bAsn7Gln, increased rat testis FSH receptor binding 2.5-fold, but decreased rat granulosa cell bioassay activity to 52% that of wild type recombinant hFSH (Flack et al., 1994) . The bAsn24Gln mutant exhibited 87% greater FSH receptor binding activity, but 59% reduced granulosa cell activity. Another laboratory reported no significant difference in FSH receptor binding activity between bAsn7Gln or bAsn24Gln mutant preparations and wild-type, CHO cell-expressed recombinant hFSH using rat testis membrane preparations (Bishop et al., 1994) . In the Sertoli cell estradiol production assay, the biologic activity of both mutants was reduced by 31% or 25%, respectively. Mutating FSHb glycosylation sites may affect hormone conformation and possibly heterodimer stability (Flack et al., 1994) . The latter could reduce activity, as heterodimeric FSH structure is necessary for high affinity FSHR binding (Fan and Hendrickson, 2005 The difference in the maximum bindable fraction was difficult to rationalize, as iodine most likely modified either Tyr 88 or Try 89 in the a subunit C-terminus (Stanton and Hearn, 1987) . Neither residue was close to the FSHb N-glycans, and changes in FSH iodination in response to altered FSHb glycosylation should have been attended by altered iodine incorporation, although a different distribution of iodine label was also possible. Saturation binding of both hFSH glycoforms confirmed the 2-fold difference in binding to rat testis FSH receptors (Fig. 4) . If the difference in bindable fraction between both tracers was responsible for the twofold greater uptake of 2.5 ng 125 I-hFSH 21/18 , then at a concentration of 3000 fmol/ml, . Instead, the 2-fold difference was retained, suggesting that FSHb glycosylation influenced the number of FSH binding sites available. As FSH receptors are now known to exist as at least dimers (Guan et al., 2010; Mazurkiewicz et al., 2006; Urizar et al., 2005) , the number of available binding sites may be affected by N-glycans of hFSH bound to one site affecting binding to a second FSH-binding site through an allosteric mechanism. However, both crystal structures of hFSH bound to the FSHR extracellular domain showed hFSHb glycans oriented away from the hormone-receptor interface, where they should have no effect on receptor binding (Fan and Hendrickson, 2005; Jiang et al., 2012) . The trimeric arrangement of enzymatically deglycosylated hFSH bound to the fulllength extracellular domain led to a proposal that the non-reducing terminus of FSHa Asn 52 glycan could occupy the binding site filled by the reducing terminal FSHa Asn 52 glycan of a second hFSH ligand (Jiang et al., 2013) . Evidence supporting this structure-based hypothesis came from modeling a biantennary glycan attached to aAsn 52 , which fit the notch between two extracellular domains normally occupied by the same glycan attached to a different FSH molecule, and from comparison of wt-and aAsn 52 mutated hFSH binding. Threefold more mutant hFSH was bound than wthFSH in saturation binding studies (Jiang et al., 2013) . The hCGa glycans in the hFSH 24 preparation could substitute for the biantennary glycan in the FSHR-ECD model because the complex branch possesses the same structure: Neu5Ac(a2-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-3), which provides the extended branch used in the modeling exercise. . Chemically deglycosylated oLH was reported to bind rat LH receptors faster than intact oLH (Liu et al., 1984) , which could have either indicated a difference in how these related receptors interacted with their ligands or reflected removal of the inhibitory influence of oLHa Asn 56 glycan (homologous to human a Asn 52 ) on LH receptor binding (Butnev, Gotschall, Butnev et al., 1998) . When trying to rationalize the presence of hFSH 21 in the most acidic hFSH isoform fractions, despite the absence of one or more N-glycans, as well as the lack of increased abundance of more negatively charged glycans in this fraction, we suggested dimerization of hFSH 21 and hFSH 24 with either glycoform. Dimerization com- bined two glycan populations and glycoforms with different overall net charges ended up in the same isoform fraction because of the average overall charge for two molecules rather than one (Bousfield et al., 2008) . Supporting evidence consisted of a small increase in molecular size indicated by Superdex 75 gel filtration (Bousfield et al., 2008) . In the present study we demonstrated that gel filtration over two Superdex 75 columns connected in series separated hFSH 24 from hFSH 21/18 (Supplement Fig. 1) . With the previous model of all-or-none glycosylation of hFSHb (Walton et al., 2001) , the rationale for the greater apparent molecular size for hFSH 24 was the presence of hFSHb 24 N-glycans that roughly doubled the narrow diameter of the hormone as compared with hFSH 21 lacking both hFSHb glycans (Bousfield et al., 2008) . Since evidence in the present study indicated that at least some of hFSHb 21 or hFSHb 18 bands represented partially glycosylated hFSHb, an alternative explanation for the higher molecular weight of hFSH 24 was that it existed as dimers of heterodimers. The orientation of hFSH heterodimers in the crystal structure of hFSH (Fox et al., 2001) including the almost complete absence of oligomannose glycans (Bousfield and Harvey, unpublished) .
Conclusion
Hypo-glycosylated hFSH represents a naturally occurring glycosylation variant that exhibits different structural and functional properties than the classical fully-glycosylated glycoform. When first discovered, we could only speculate that hypo-glycosylated hFSH action differed, perhaps by providing an episodic signal to the gonads, much like has been demonstrated for LH in peripheral circulation (Padmanabhan et al., 1997; Plant et al., 1978; Reame et al., 1984) . The present study shows that hypo-glycosylated hFSH binds the FSH receptor more rapidly and can access more binding sites than fully glycosylated hFSH. In sheep hypothalamo-hypophysial portal blood, episodic release of FSH was demonstrated that could not be detected in peripheral blood, at least in part due to a high background of tonic FSH secretion (Padmanabhan et al., 1997) . Episodically released hypo-glycosylated hFSH might contribute to this pattern if it is cleared rapidly, as expected from recombinant hFSH glycosylation mutant clearance studies (Bishop et al., 1995) . Rapid clearance involves escape from capillaries, and in the gonads, this can mean rapid FSH delivery to target cells where hypo-glycosylated hFSH can quickly bind and activate FSH receptors. Thus, the apparent loss of hypo-glycosylated FSH as a function of age may contribute to reduced fertility associated with aging. The effects of reduced hFSH 21 abundance would be manifested around the time of ovulation, when a recent report suggests such hypo-glycosylated hFSH concentrations are elevated in the circulation (Wide and Ericksson, 2013) . Loss of this form could adversely affect follicle development (West et al., 2002) and oocyte maturation (Andersen et al., 2001) , thereby contributing to infertility.
